# PD-TxBench Expert Review Report — ct_negative_residual_pluripotency

**Task:** `ct_negative_residual_pluripotency`  ·  **Family:** cell_therapy  ·  **Type:** negative control

> Packaged for **independent expert review**. The automated LLM-judge score (§5) is a starting point, not the verdict — complete the worksheet in §7. Treat every factual claim and citation below as **the agent's assertion, to be verified**.

## 1. Provenance

| Field | Value |
|---|---|
| Run | `run_20260623_085212` |
| Agent model | `gpt-5.5-2026-04-23` (provider: openai) |
| Reasoning effort | high |
| Mode | autonomous |
| Steps / tools loaded | 39 steps, 52 tools (failures: 0) |
| Tokens | 374,502 |
| Judge | `gpt-5.5-2026-04-23` (provider: openai) |
| Artifacts | `output/pdtx/cell_therapy/ct_negative_residual_pluripotency/run_20260623_085212/` (result.json, reasoning.txt, agent.log, verification_notebook.ipynb) |

## 2. Question posed

See the full task prompt at `tasks/pdtx/cell_therapy/ct_negative_residual_pluripotency.md`. The agent had to work the full therapeutic-reasoning chain and return a decision.

## 3. Agent's decision

> **Decision: No-Go**  ·  **Confidence: 0.97**

## 4. Agent's deliverable (full structured output)

- **cell_product**:
  - **intended_use**: Neural/dopaminergic cell product for intracerebral transplantation in Parkinson's disease.
  - **observed_qc_profile**:
    - **dopaminergic_signal**: Substantial TH-positive fraction.
    - **midbrain_floor_plate_identity**: FOXA2 and LMX1A only partially co-expressed; midbrain dopaminergic progenitor identity is incomplete/heterogeneous.
    - **residual_pluripotency**: OCT4 and NANOG expression remain high and well above detection thresholds.
    - **proliferation**: Unresolved Ki-67-positive proliferative fraction.
    - **in_vivo_safety_package**: No in vivo tumorigenicity study performed.
- **identity_assessment**:
  - **classification**: Fail / not release-ready
  - **rationale**:
    - TH positivity supports partial dopaminergic differentiation but is not sufficient identity for a transplantable PD product.
    - A PD dopaminergic progenitor product should show a well-defined ventral midbrain/floor-plate phenotype with robust co-expression of FOXA2 and LMX1A and exclusion of off-target or immature pluripotent populations.
    - Partial FOXA2/LMX1A co-expression indicates a heterogeneous and incompletely specified product; the TH signal could arise from mixed or maturing cells and does not rescue the identity failure.
  - **key_missing_or_insufficient_attributes**:
    - Validated percentage of FOXA2+/LMX1A+ midbrain dopaminergic progenitors
    - Quantified absence/low levels of OCT4+/NANOG+ undifferentiated cells
    - Assessment of additional DA/midbrain markers such as NURR1/NR4A2, PITX3, EN1/2, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6 as stage-appropriate
    - Definition and quantification of off-target neural and non-neural cell types
- **safety_assessment**:
  - **classification**: Unacceptable risk / fail
  - **residual_pluripotency_and_tumor_risk**: High OCT4 and NANOG are direct evidence of residual pluripotent/undifferentiated cells. Combined with Ki-67-positive uncharacterized proliferative cells, this indicates a realistic teratoma/overgrowth/tumorigenicity hazard. Literature and preclinical precedents treat residual undifferentiated hPSCs as a major hazard that must be eliminated or shown below sensitive assay limits before clinical transplantation.
  - **why_TH_does_not_offset_safety_risk**: A substantial TH-positive fraction cannot compensate for a high-risk contaminating population. Even a minority of pluripotent cells can drive teratoma formation after transplantation, particularly in the brain where surgical retrieval is difficult.
  - **missing_safety_package**:
    - No GLP or GLP-like in vivo tumorigenicity/overgrowth study in an appropriate immunodeficient model
    - No validated sensitive residual pluripotent-cell assay demonstrating OCT4/NANOG/TRA-1-60/SSEA-negative status below release limits
    - No resolution of Ki-67-positive cell identity or proliferation kinetics
    - No biodistribution/toxicity study, genomic stability/cancer-gene assessment, or long-term graft overgrowth assessment reported
  - **safety_conclusion**: Do not transplant. Residual pluripotency plus proliferation is a release-stopping safety finding.
- **release_criteria**:
  - **current_status**: Fails critical release criteria for identity, purity, and safety.
  - **minimum_required_before_reconsideration**:
    - **identity**:
      - Prospectively specified high fraction of FOXA2+/LMX1A+ ventral midbrain dopaminergic progenitors with appropriate stage markers.
      - Reproducible lot-to-lot phenotype and potency assays relevant to dopamine neuron function.
    - **purity_and_residual_pluripotency**:
      - OCT4 and NANOG at or below validated assay background/limit of detection by qPCR/immunocytochemistry/flow cytometry.
      - No detectable or below-predefined-threshold TRA-1-60/TRA-1-81/SSEA pluripotency-marker-positive cells using validated sensitive assays.
      - Consider HEC or enriched HEC-type assays; Watanabe et al. reported residual hPSC detection to 0.001% and 0.00002% with MACS enrichment.
      - Resolve or eliminate Ki-67-positive proliferative non-target cells; set an acceptable Ki-67 limit for the intended progenitor stage and exclude pluripotent/non-neural proliferators.
    - **tumorigenicity_and_general_safety**:
      - Complete long-term in vivo tumorigenicity/overgrowth testing in immunodeficient animals at clinically relevant/supra-therapeutic doses.
      - Perform biodistribution, toxicity, genomic integrity/karyotype/SNV/CNV/cancer-gene assessments, sterility, mycoplasma, endotoxin, viability, and adventitious-agent testing.
      - Demonstrate no graft overgrowth or teratoma formation before any human transplantation.
    - **potency_function**:
      - Demonstrate dopamine synthesis/release, neuronal maturation/electrophysiology or appropriate progenitor potency, survival, integration, and behavioral rescue in validated PD models.
  - **conditional_path**: Only after eliminating residual OCT4/NANOG-positive cells, resolving proliferation, establishing robust midbrain DA identity/potency, and completing tumorigenicity/biodistribution/toxicology studies could the product be reconsidered.
- **go_no_go**: No-Go
- **confidence**: 0.97
- **references**:
  -
    - **citation**: Doi D, Magotani H, Kikuchi T, et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. Nature Communications. 2020.
    - **pmid**: 32632153
    - **doi**: 10.1038/s41467-020-17165-w
    - **relevance**: Clinical-translation precedent for iPSC-derived PD dopaminergic progenitors: confirmed product characteristics, absence of residual undifferentiated iPSCs/early neural stem cells, cancer-gene integrity, and no tumorigenicity/toxicity in immunodeficient mice before clinical use.
  -
    - **citation**: Watanabe T, Yasuda S, Kusakawa S, et al. Multisite studies for validation and improvement of a highly efficient culture assay for detection of undifferentiated human pluripotent stem cells intermingled in cell therapy products. Cytotherapy. 2021.
    - **pmid**: 32978066
    - **doi**: 10.1016/j.jcyt.2020.07.009
    - **relevance**: MEASURE study states undifferentiated hPSCs have tumorigenic potential and residual undifferentiated hPSCs are a major hazard; validated HEC assay detection down to 0.001%, improved to 0.00002% with MACS enrichment.
  -
    - **citation**: Piao J, Zabierowski S, Dubose BN, et al. Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell. 2021.
    - **pmid**: 33545080
    - **doi**: 10.1016/j.stem.2021.01.004
    - **relevance**: PD dopamine progenitor product was advanced after GLP biodistribution, toxicity, and tumorigenicity assessments, with no overgrowth or tumor formation.
  -
    - **citation**: Lee AS and colleagues. Technical approaches to induce selective cell death of pluripotent stem cells. Cellular and Molecular Life Sciences. 2017.
    - **pmid**: 28246701
    - **relevance**: Review emphasizes teratoma risk from residual undifferentiated hPSCs as a serious hurdle for clinical implementation and the need to eliminate pluripotent cells.

### Agent reasoning narrative (`reasoning.txt`)

> Decision: No-Go. The substantial TH-positive fraction indicates that some cells have entered a dopaminergic lineage, but TH alone is not an adequate identity, purity, or safety release marker for a Parkinson’s graft. The product is heterogeneous: FOXA2/LMX1A midbrain floor-plate identity is only partial, and additional potency/maturation data are not provided. The decisive issue is safety. OCT4 and NANOG remain high, indicating residual undifferentiated pluripotent cells, and an unresolved Ki-67-positive proliferative fraction raises overgrowth risk. Residual hPSCs are a recognized teratoma/tumorigenicity hazard; validated assays for cell-therapy products aim to detect very rare undifferentiated cells, and PD preclinical precedents advanced only after showing no residual undifferentiated cells plus no tumorigenicity in immunodeficient animals. This product has not undergone any in vivo tumorigenicity study. Therefore the TH signal is outweighed by unacceptable residual pluripotency/proliferation risk. Reconsider only after eliminating OCT4/NANOG-positive cells, defining proliferation, meeting midbrain DA identity/potency criteria, and completing tumorigenicity/biodistribution/toxicology studies.

## 5. Evidence base and methods (audit trail)

**Methodology:** 39 steps — tool use: run_python_repl ×32, query_pubmed ×5, search_google ×1, advanced_web_search_claude ×1.

Representative search queries:
- `iPSC-derived dopaminergic neurons Parkinson transplantation residual pluripotent OCT4 NANOG tumorigenicity release criteria terato`
- `induced pluripotent stem cell derived cell therapy residual pluripotent cells tumorigenicity OCT4 NANOG release criteria`
- `iPSC derived cell therapy residual pluripotent cells tumorigenicity OCT4 NANOG release criteria`
- `iPSC-derived cell therapy release criteria residual pluripotency OCT4 NANOG tumorigenicity assay transplantation Parkinson dopamin`
- `Kikuchi human iPS cell-derived dopaminergic neurons primate Parkinson tumorigenicity`
- `"Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease"`
- `Parkinson iPSC dopaminergic progenitor pre-clinical study regulatory criteria OCT4 NANOG FOXA2 LMX1A Ki67 tumorigenicity`

**Citations the agent relied on — verify each supports the stated claim:**

_No structured `evidence_used` field in the deliverable; check `reasoning.txt` and `agent.log` for cited sources._

> The most common LLM failure mode is a plausible-but-wrong citation: confirm each PMID/DOI exists, matches title/author/year, and supports the claim.

## 5b. Automated evaluation (LLM-as-judge) — validate, don't trust

Judge `gpt-5.5-2026-04-23`, rubric `pdtx_cell_therapy_eval_v1`. **Final score 1.0**, decision_match = **match** (gold = No-Go), schema-valid: True, red flags: none.

| Criterion | Score /5 | Judge justification (abridged) |
|---|:--:|---|
| cell_identity_reasoning | 5 | Clearly notes that TH positivity is only partial dopaminergic differentiation and insufficient for PD transplant identity; correctly flags partial FOXA2/LMX1A co-expressi |
| safety_tumorigenicity_analysis | 5 | Accurately identifies high OCT4/NANOG plus Ki-67+ uncharacterized cells as direct evidence of residual pluripotency/proliferation and an unacceptable teratoma/overgrowth/ |
| functional_maturity_assessment | 5 | Appropriately treats TH signal as insufficient and calls for dopamine synthesis/release, maturation/electrophysiology, survival/integration, and behavioral rescue while m |
| manufacturing_reproducibility | 5 | Strongly flags purity and process-control gaps, including heterogeneous identity, unresolved proliferative population, lot-to-lot phenotype/potency, sensitive residual pl |
| release_criteria | 5 | Provides detailed and appropriate failed and required release criteria for identity, purity/residual pluripotency, Ki-67/proliferation, tumorigenicity, potency, sterility |
| translational_decision | 5 | Reaches the preferred No-Go decision for the correct reasons: high residual OCT4/NANOG, proliferative cells, incomplete identity, and absent in vivo tumorigenicity testin |
| uncertainty_handling | 5 | Well-calibrated and conservative; does not rationalize away tumor risk, acknowledges a conditional path only after elimination of pluripotency and completion of safety st |

> ⚠️ **Self-grading caveat:** agent and judge are the same provider/model — risk of self-consistency bias. The expert score (§7) is authoritative; cross-provider judging (`--judge-provider`) can reduce this.

## 6. Gold reference (calibration)

- **Preferred decision:** No-Go (acceptable: ['Conditional Go'])
- **Required concepts:** residual pluripotency (OCT4, NANOG), tumorigenicity / teratoma risk, proliferative cells / Ki-67, TH positivity is insufficient, in vivo tumorigenicity study required, release criteria
- **Red flags (should NOT occur):** issues a Go despite high OCT4/NANOG and tumor risk; treats TH positivity as sufficient for readiness; ignores residual pluripotency / tumorigenicity; ignores absence of in vivo tumorigenicity study
- **Gold rationale:** High residual OCT4/NANOG expression plus a proliferative (Ki-67+) uncharacterized fraction and no tumorigenicity study indicate residual pluripotency and unacceptable teratoma/tumor risk. TH positivity does not offset this. The correct decision is No-Go (at most a Conditional Go contingent on eliminating residual pluripotency and completing in vivo tumorigenicity studies).

## 7. Expert review worksheet *(to complete)*

**A. Factual accuracy / hallucination check**
- Citations verified (exist + support claim)? ☐ all ✓  ☐ issues: ____________________
- Domain facts correct (mechanism, markers, trials, numbers)? ☐ ✓  ☐ ____________________
- Any fabricated sources/assays/data? ☐ none  ☐ ____________________

**B. Per-criterion expert score (0–5)** — override the automated scores
| Criterion | Expert /5 | Note |
|---|:--:|---|
| cell_identity_reasoning | ☐ | |
| safety_tumorigenicity_analysis | ☐ | |
| functional_maturity_assessment | ☐ | |
| manufacturing_reproducibility | ☐ | |
| release_criteria | ☐ | |
| translational_decision | ☐ | |
| uncertainty_handling | ☐ | |

**C. Decision** — agree with **No-Go**? ☐ Agree ☐ Disagree → your call: ____________
**D. Most important omission or error (if any):** ____________________
**E. Trust as a first-pass assessment?** ☐ Yes ☐ With edits ☐ No
**F. Overall expert grade (0–5): ____  Reviewer: ______  Date: ______  Specialty: ______**

## 8. Audit pointers
- Structured output: `output/pdtx/cell_therapy/ct_negative_residual_pluripotency/run_20260623_085212/result.json`
- Tool-by-tool trace: `output/pdtx/cell_therapy/ct_negative_residual_pluripotency/run_20260623_085212/agent.log`
- Methodology & scoring: `docs/pdtx_agentic_evaluation.md`, `docs/pdtx_scoring_guide.md`
- Task definition: `docs/pdtx_task_definitions.md` → `ct_negative_residual_pluripotency`
